is a Professor of Radiation Oncology and Pathology at the University of Maryland, School of Medicine in Baltimore, is recognized internationally as an expert on the effects of radiation on the hematopoietic and gastrointestinal systems in large animal models and their treatment, in vivo, with supportive care and selected organ-specific medical countermeasures against acute and delayed effects of acute radiation exposure.

He earned MS and PhD degrees in radiation biology at the State University of New York at Buffalo and has more than 40 y of experience as a radiobiologist in the field of experimental hematology and the effects of acute radiation exposure. He has published 207 peer-reviewed manuscripts and 47 chapters in books or proceedings. He has co-edited five books published from international meetings organized on radiation effects and treatment.

Dr. MacVittie has served as an advisor to the World Health Organization Collaborating Centers in Radiation Emergency Medical Preparedness and Assistance and as a member of the North Atlantic Treaty Organization’s Radiation Research Study groups and the Task Group for the International Council on Radiation Protection entitled “Radiation Effects on Normal Tissue.” Dr. MacVittie also served on the inaugural National Biodefense Science Board Federal Advisory Committee.

The MacVittie Laboratory has developed an Animal Model Research Platform that positions the research team to carry the lead in an integrated effort to develop the most effective products to treat the acute radiation syndrome (ARS) and the delayed effects of acute radiation exposure to include a strategic focus on MCM efficacy against multiple organ injury, both acute and delayed.

The MacVittie Research Team and its accumulated data base served as the focal point for recent efforts to design the initial “pivotal” trials in nonhuman primates to determine the treatment efficacy of neupogen and neulasta to treat potentially lethally irradiated personnel. These are the first two MCM approved by the U.S. Food and Drug Administration under the “animal rule” to treat the hematopoietic ARS.